The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data

AIM: Oral risedronate is effective in the treatment of postmenopausal osteoporosis when administered daily, weekly, or monthly. In this 1-year, randomized, double-blind, multicenter study we compared the weekly 35-mg and daily 5-mg risedronate dosing regimens in the treatment of Chinese postmenopaus...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Acta Pharmacol Sin
Glavni autori: Gu, Jie-mei, Wang, Li, Lin, Hua, Chen, De-cai, Tang, Hai, Jin, Xiao-lan, Xia, Wei-bo, Hu, Yun-qiu, Fu, Wen-zhen, He, Jin-wei, Zhang, Hao, Wang, Chun, Yue, Hua, Hu, Wei-wei, Liu, Yu-juan, Zhang, Zhen-lin
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2015
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648111/
https://ncbi.nlm.nih.gov/pubmed/26051110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2015.30
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items